Relief from digital vasospasm by treatment with captopril and its complete inhibition by serine proteinase inhibitors in Raynaud's phenomenon.
作者信息
Miyazaki S, Miura K, Kasai Y, Abe K, Yoshinaga K
出版信息
Br Med J (Clin Res Ed). 1982 Jan 30;284(6312):310-11. doi: 10.1136/bmj.284.6312.310.
Abstract
摘要
相似文献
1
Relief from digital vasospasm by treatment with captopril and its complete inhibition by serine proteinase inhibitors in Raynaud's phenomenon.卡托普利治疗可缓解雷诺现象中的指端血管痉挛，且丝氨酸蛋白酶抑制剂可完全抑制该现象。
Br Med J (Clin Res Ed). 1982 Jan 30;284(6312):310-11. doi: 10.1136/bmj.284.6312.310.
2
Treatment of Raynaud's phenomenon with captopril.卡托普利治疗雷诺现象
Drugs Exp Clin Res. 1987;13(1):37-42.
3
[Treatment of Raynaud's syndrome with captopril].
Dtsch Med Wochenschr. 1984 Jun 1;109(22):857-60. doi: 10.1055/s-2008-1069287.
4
The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon.卡托普利对原发性雷诺现象患者皮肤血流的影响。
Br J Dermatol. 1987 Dec;117(6):751-8. doi: 10.1111/j.1365-2133.1987.tb07356.x.
5
[Raynaud's disease treated with captopril (Capoten). A randomized double-blind cross-over study].[用卡托普利（开博通）治疗雷诺病。一项随机双盲交叉研究]
Ugeskr Laeger. 1984 Sep 3;146(36):2695-7.
6
A plethysmographic study of the effect of tetranicotinoylfructose (Bradilan) on digital blood flow in primary and secondary Raynaud's phenomenon.四烟酰果糖（布拉地兰）对原发性和继发性雷诺现象中手指血流影响的体积描记法研究
Angiology. 1974 May;25(5):312-6. doi: 10.1177/000331977402500503.
7
Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.使用5-羟色胺2受体拮抗剂酮色林治疗雷诺现象。
Br Med J (Clin Res Ed). 1982 Oct 16;285(6348):1069-71. doi: 10.1136/bmj.285.6348.1069.
8
Laser-Doppler flowmetry in the assessment of "mild" Raynaud's phenomenon and its treatment.激光多普勒血流仪在评估“轻度”雷诺现象及其治疗中的应用
Panminerva Med. 1990 Oct-Dec;32(4):151-4.
9
Angiotensin converting enzyme inhibitors in Raynaud's phenomenon.
Drugs. 1994 Dec;48(6):864-7. doi: 10.2165/00003495-199448060-00003.
10
Role of digital artery adrenoceptors in Raynaud's disease.数字动脉肾上腺素能受体在雷诺病中的作用。
Vasc Med. 1997;2(1):1-7. doi: 10.1177/1358863X9700200101.
引用本文的文献
1
Decision analysis applied to the selection of angiotensin-converting enzyme inhibitors.
Pharm World Sci. 1993 Oct 15;15(5):219-24. doi: 10.1007/BF01880630.
2
Angiotensin converting enzyme inhibitors in Raynaud's phenomenon.
Drugs. 1994 Dec;48(6):864-7. doi: 10.2165/00003495-199448060-00003.
3
Adverse reactions with angiotensin converting enzyme (ACE) inhibitors.血管紧张素转换酶（ACE）抑制剂的不良反应。
Med Toxicol. 1986 Mar-Apr;1(2):122-41. doi: 10.1007/BF03259832.
4
Pathogenesis and treatment of Raynaud's phenomenon.
Cardiovasc Drugs Ther. 1990 Jan;4 Suppl 1:45-51. doi: 10.1007/BF00053426.
5
Subjective and objective assessment of enalapril in primary Raynaud's phenomenon.依那普利治疗原发性雷诺现象的主观和客观评估
Br J Clin Pharmacol. 1991 Apr;31(4):477-80. doi: 10.1111/j.1365-2125.1991.tb05565.x.
6
Raynaud's phenomenon: its relevance to scleroderma.雷诺现象：其与硬皮病的相关性。
Ann Rheum Dis. 1991 Nov;50 Suppl 4(Suppl 4):839-45. doi: 10.1136/ard.50.suppl_4.839.
本文引用的文献
1
Role of kinins in the acute antihypertensive effect of the converting enzyme inhibitor, captopril.激肽在转化酶抑制剂卡托普利急性降压作用中的作用。
Hypertension. 1981 Jan-Feb;3(1):18-22. doi: 10.1161/01.hyp.3.1.18.
2
Evidence for participation of kinins in the antihypertensive effect of converting enzyme inhibition.
Klin Wochenschr. 1981 Jan 15;59(2):69-74. doi: 10.1007/BF01477285.
3
Inhibitory effects of -guanidino acid esters on trypsin, plasmin, plasma kallikrein and thrombin.胍基酸酯对胰蛋白酶、纤溶酶、血浆激肽释放酶和凝血酶的抑制作用。
Biochim Biophys Acta. 1972 Apr 7;268(1):221-4. doi: 10.1016/0005-2744(72)90218-5.
4
Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade.口服血管紧张素转换酶抑制剂逆转硬皮病的血管和肾脏危象
N Engl J Med. 1979 Jun 21;300(25):1417-9. doi: 10.1056/NEJM197906213002505.
5
Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents.血管紧张素转换酶特异性抑制剂的设计：新型口服活性抗高血压药物
Science. 1977 Apr 22;196(4288):441-4. doi: 10.1126/science.191908.
Zotero 插件